Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers

  • Felix Stickel
  • Philipp Lutz
  • Stephan Buch
  • Hans Dieter Nischalke
  • Ines Silva
  • Vanessa Rausch
  • Janett Fischer
  • Karl Heinz Weiss
  • Daniel Gotthardt
  • Jonas Rosendahl
  • Astrid Marot
  • Mona Elamly
  • Marcin Krawczyk
  • Markus Casper
  • Frank Lammert
  • Thomas Wm Buckley
  • Andrew McQuillin
  • Ulrich Spengler
  • Florian Eyer
  • Arndt Vogel
  • Silke Marhenke
  • Johann von Felden
  • Henning Wege
  • Rohini Sharma
  • Stephen Atkinson
  • Andre Franke
  • Sophie Nehring
  • Vincent Moser
  • Clemens Schafmayer
  • Laurent Spahr
  • Carolin Lackner
  • Rudolf E Stauber
  • Ali Canbay
  • Alexander Link
  • Luca Valenti
  • Jane I Grove
  • Guruprasad P Aithal
  • Jens U Marquardt
  • Waleed Fateen
  • Steffen Zopf
  • Jean-Francois Dufour
  • Jonel Trebicka
  • Christian Datz
  • Pierre Deltenre
  • Sebastian Mueller
  • Thomas Berg
  • Jochen Hampe
  • Marsha Y Morgan

Beteiligte Einrichtungen

Abstract

BACKGROUND AND AIMS: Carriage of rs738409:G in patatin-like phospholipase domain containing 3 (PNPLA3) is associated with an increased risk for developing alcohol-related cirrhosis and hepatocellular carcinoma (HCC). Recently, rs72613567:TA in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) was shown to be associated with a reduced risk for developing alcohol-related liver disease and to attenuate the risk associated with carriage of PNPLA3 rs738409:G. This study explores the risk associations between these two genetic variants and the development of alcohol-related cirrhosis and HCC.

APPROACH AND RESULTS: Variants in HSD17B13 and PNPLA3 were genotyped in 6,171 participants, including 1,031 with alcohol-related cirrhosis and HCC, 1,653 with alcohol-related cirrhosis without HCC, 2,588 alcohol misusers with no liver disease, and 899 healthy controls. Genetic associations with the risks for developing alcohol-related cirrhosis and HCC were determined using logistic regression analysis. Carriage of HSD17B13 rs72613567:TA was associated with a lower risk for developing both cirrhosis (odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72-0.88; P = 8.13 × 10-6 ) and HCC (OR, 0.77; 95% CI, 0.68-0.89; P = 2.27 × 10-4 ), whereas carriage of PNPLA3 rs738409:G was associated with an increased risk for developing cirrhosis (OR, 1.70; 95% CI, 1.54-1.88; P = 1.52 × 10-26 ) and HCC (OR, 1.77; 95% CI, 1.58-1.98; P = 2.31 × 10-23 ). These associations remained significant after adjusting for age, sex, body mass index, type 2 diabetes, and country. Carriage of HSD17B13 rs72613567:TA attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men and women, but the protective effect against the subsequent development of HCC was only observed in men (ORallelic , 0.75; 95% CI, 0.64-0.87; P = 1.72 × 10-4 ).

CONCLUSIONS: Carriage of variants in PNPLA3 and HSD17B13 differentially affect the risk for developing advanced alcohol-related liver disease. A genotypic/phenotypic risk score might facilitate earlier diagnosis of HCC in this population.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0270-9139
DOIs
StatusVeröffentlicht - 07.2020

Anmerkungen des Dekanats

© 2019 by the American Association for the Study of Liver Diseases.

PubMed 31630428